Korro Bio (KRRO) SVP Dolan sells 3,383 shares to cover RSU taxes

Filing Impact

(Neutral)

Filing Sentiment

(Negative)

Form Type

Rhea-AI Filing Summary

Korro Bio, Inc. Senior Vice President of Finance Oliver Dolan reported an open-market sale of 3,383 shares of common stock on June 16, 2026 at a weighted-average price of $10.83 per share. According to the footnotes, this was a mandatory sale solely to cover tax withholding obligations arising from the vesting and settlement of restricted stock units (RSUs) granted under the company’s 2023 Stock Option and Incentive Plan.

After this transaction, Dolan holds 18,099 shares of common stock directly, which includes 10,741 shares issuable upon settlement of an RSU that is scheduled to vest on December 15, 2026, provided he maintains a continuous service relationship through that date.

Insider Trade Summary

Net Seller: 3,383 shares ($36,638)

Net Sell 1 txn

Insider Dolan Oliver

Role Senior Vice President, Finance

Sold 3,383 shs ($37K)

Type	Security	Shares	Price	Value
Sale	Common Stock	3,383	$10.83	$37K

Holdings After Transaction: Common Stock — 18,099 shares (Direct, null)

Footnotes (1)

Represents the mandatory sale of shares of common stock solely to satisfy tax withholding obligations incurred upon vesting and settlement of a restricted stock unit (RSU) granted under the Issuer's 2023 Stock Option and Incentive Plan (the 2023 Plan). The price reported in Column 4 is a weighted-average price. The shares were sold in multiple transactions at prices ranging from $10.58 to $11.35, inclusive. Full information regarding the number of shares sold at each separate price can be provided to the issuer, any security holder of the issuer or the staff of the Securities and Exchange Commission upon request. Includes 10,741 shares of common stock issuable upon settlement of a RSU granted under the 2023 Plan that will vest on December 15, 2026 subject to the reporting person maintaining a continuous Service Relationship (as defined in the 2023 Plan) through such date.

Key Figures

Shares sold: 3,383 shares Weighted-average sale price: $10.83/share Post-transaction holdings: 18,099 shares +2 more

5 metrics

Shares sold 3,383 shares Open-market sale on June 16, 2026

Weighted-average sale price $10.83/share Common stock sale on June 16, 2026

Post-transaction holdings 18,099 shares Common stock held directly after transaction

Unvested RSU shares 10,741 shares RSU under 2023 Plan vesting December 15, 2026

Sale price range $10.58–$11.35/share Multiple transactions underlying the weighted-average price

Key Terms

restricted stock unit (RSU), weighted-average price, 2023 Stock Option and Incentive Plan, tax withholding obligations

4 terms

restricted stock unit (RSU) financial

"upon vesting and settlement of a restricted stock unit (RSU) granted under the Issuer's 2023 Stock Option and Incentive Plan"

A restricted stock unit (RSU) is a promise from a company to give an employee company shares (or cash equal to their value) at a future date if certain conditions are met, such as staying with the company or hitting performance targets. For investors, RSUs matter because when they convert into actual shares they increase the number of shares available and can create selling pressure as employees cash out—think of them as a future paycheck paid in company stock.

weighted-average price financial

"The price reported in Column 4 is a weighted-average price."

2023 Stock Option and Incentive Plan financial

"granted under the Issuer's 2023 Stock Option and Incentive Plan (the 2023 Plan)."

tax withholding obligations financial

"mandatory sale of shares of common stock solely to satisfy tax withholding obligations incurred upon vesting"

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Form 4 Insider Transactions: What Each Field Means →

06/17/2026 - 04:05 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Dolan Oliver

(Last)

(First)

(Middle)

C/O KORRO BIO, INC.

60 FIRST STREET, 2ND FLOOR, SUITE 250

(Street)

CAMBRIDGE

MASSACHUSETTS

02141

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Korro Bio, Inc. [ KRRO ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	Senior Vice President, Finance

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/16/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	06/16/2026		S⁽¹⁾		3,383	D	$10.83⁽²⁾	18,099⁽³⁾	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:

1. Represents the mandatory sale of shares of common stock solely to satisfy tax withholding obligations incurred upon vesting and settlement of a restricted stock unit (RSU) granted under the Issuer's 2023 Stock Option and Incentive Plan (the 2023 Plan).

2. The price reported in Column 4 is a weighted-average price. The shares were sold in multiple transactions at prices ranging from $10.58 to $11.35, inclusive. Full information regarding the number of shares sold at each separate price can be provided to the issuer, any security holder of the issuer or the staff of the Securities and Exchange Commission upon request.

3. Includes 10,741 shares of common stock issuable upon settlement of a RSU granted under the 2023 Plan that will vest on December 15, 2026 subject to the reporting person maintaining a continuous Service Relationship (as defined in the 2023 Plan) through such date.

	/s/ Jeffrey Cerio, Attorney-in-fact	06/17/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What insider transaction did Korro Bio (KRRO) report for Oliver Dolan?

Korro Bio reported that Senior Vice President of Finance Oliver Dolan sold 3,383 shares of common stock at a weighted-average price of $10.83. The sale was mandatory to satisfy tax withholding obligations from vested restricted stock units under the company’s 2023 stock plan.

Was the KRRO insider sale by Oliver Dolan a discretionary trade?

The sale was described as mandatory and executed solely to cover tax withholding obligations from vesting and settlement of RSUs. This indicates a tax-related transaction under the 2023 Stock Option and Incentive Plan, rather than a discretionary open-market sale driven by personal investment decisions.

How many Korro Bio (KRRO) shares did Oliver Dolan sell and at what price?

Oliver Dolan sold 3,383 shares of Korro Bio common stock at a weighted-average price of $10.83 per share. Footnotes state the shares were sold in multiple trades between $10.58 and $11.35, and detailed breakdowns are available upon request to the company or regulators.

What are Oliver Dolan’s holdings in Korro Bio (KRRO) after this Form 4 transaction?

After the reported transaction, Oliver Dolan holds 18,099 shares of Korro Bio common stock directly. This figure includes 10,741 shares issuable upon settlement of an RSU grant scheduled to vest on December 15, 2026, contingent on his continued service relationship with the company.

What RSU award terms were disclosed for Korro Bio (KRRO) executive Oliver Dolan?

The filing notes an RSU award covering 10,741 shares of Korro Bio common stock under the 2023 Stock Option and Incentive Plan. These RSUs are expected to vest on December 15, 2026, provided Oliver Dolan maintains a continuous service relationship with Korro Bio through that date.

How was the sale price range described in the Korro Bio (KRRO) Form 4 filing?

The weighted-average sale price reported was $10.83 per share. Footnotes clarify the shares were sold in multiple transactions at prices ranging from $10.58 to $11.35, and more detailed trade information can be obtained from Korro Bio, any security holder, or SEC staff upon request.